Adoptive cell transfer: a clinical path to effective cancer immunotherapy
- PMID: 18354418
- PMCID: PMC2553205
- DOI: 10.1038/nrc2355
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Abstract
Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.
Figures






Comment in
-
Immunotherapy: Vaccine trials in melanoma -- time for reflection.Nat Rev Clin Oncol. 2009 May;6(5):256-8. doi: 10.1038/nrclinonc.2009.42. Nat Rev Clin Oncol. 2009. PMID: 19390551
References
-
-
Rosenberg SA, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 1988;319:1676–1680.The first paper to demonstrate the regression of cancer using TIL for the immunotherapy of patients with metastatic melanoma.
-
-
-
Dudley ME, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005;23:2346–2357.Reference 2 and Reference 3 demonstrate that lymphodepletion prior to ACT can lead to increased cancer regression as well as clonal repopulation of patients with anti-tumour lymphocytes.
-
-
-
Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–129.The first paper demonstrating the adoptive cell transfer of lymphocytes transduced with a retrovirus encoding TCRs that recognize a cancer antigen can mediate anti-tumour responses in patients with metastatic melanoma.
-
-
- Rosenberg SA, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985;313:1485–1492. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical